MGLL and tic disorder: Although some new pharmacological compounds are currently under investigation to treat tics, first results were disappointing: both the vesicular monoamine transport (VMAT) inhibitor deutetrabenazine [16] as well as the inhibitor of the monoacylglycerol lipase (MAGL) and selective modulator of the endocannabinoid system Lu AG06466 (former ABX-1431) [10] did not meet the primary endpoint of tic reduction in phase 2/3 studies.